Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 3/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4253037 | 0.93 | MAPT (0.60) | MAPTHTR2AHTR7HTR1ADRD2 | |
| SCHEMBL4391668 | 0.87 | MAPT (0.54) | MAPTHTR2AHTR7HTR1ADRD2 | |
| SCHEMBL4240900 | 0.87 | MAPT (0.54) | MAPTHTR2AHTR7HTR1ADRD2 | |
| SCHEMBL4396325 | 0.87 | MAPT (0.54) | MAPTHTR2AHTR7HTR1ADRD2 | |
| SCHEMBL4394614 | 0.87 | MAPT (0.59) | MAPTHTR2AHTR7HTR6HTR1A | |
| SCHEMBL4254360 | 0.87 | HTR7 (0.56) | MAPTHTR7L3MBTL1LMNAALDH1A1 | |
| SCHEMBL4245787 | 0.85 | MAPT (0.67) | MAPTDRD3L3MBTL1LMNAALDH1A1 | |
| SCHEMBL4395226 | 0.85 | MAPT (0.67) | MAPTDRD3L3MBTL1LMNAALDH1A1 | |
| SCHEMBL4252387 | 0.85 | SMN1; SMN2 (0.53) | MAPTL3MBTL1LMNAKDM4EDRD4 | |
| SCHEMBL4249510 | 0.83 | MAPT (0.45) | MAPTHTR2AHTR7HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | claimed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | claimed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | claimed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | claimed |
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2009-12-10 | — | — | US | disclosed |
| CN-101490010-A | Compounds and compositions as ITPKB inhibitors | IRM LLC (VG) | 2009-07-22 | — | — | CN | disclosed |
| EP-2057124-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM, LLC (BM) | 2009-05-13 | — | — | EP | disclosed |
| WO-2008011611-A2 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306039-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IP6K1, IP6K2, IP6K3 | MAPT 3880/4885HTR2A 4524/4885HTR7 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.